Biolegend, 423114, Zombie Violet™ Fixable Viability Kit
500tests
Catalog Number: 423114
Send an RFQ.
Category
Pack Size1 vial
| Preparation | Zombie Violet™ Fixable Viability Kit is composed of lyophilized Zombie Violet™ dye and anhydrous DMSO. For reconstitution, bring the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Violet™ dye until fully dissolved. 100 tests = 1 vial of Zombie Violet™ + DMSO, 500 tests = 5 vials of Zombie Violet™ + DMSO. |
|---|---|
| Storage & Handling | Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Violet™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month. |
| Application | FC - Quality tested ICFC, ICC - Verified |
| Recommended Usage | Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunocytochemistry, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type. |
| Excitation Laser | Violet Laser (405 nm) |
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Application Notes |
|---|
| Zombie Violet™ dye is excited by the Violet laser (405 nm) and has fluorescence emission maximum at 423 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Violet™ dye has similar emission to Brilliant Violet 421™. Standard Cell Staining Protocol: Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrifuge to ensure the reagent is at the bottom of the vial. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Violet™ dye and mix until fully dissolved Wash cells with PBS buffer (no Tris buffer and protein free). Dilute Zombie Violet™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie Violet™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA. Continue performing antibody staining procedure as desired. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation. No-wash Sequential Staining Protocol: Wash cells with PBS buffer (no Tris buffer and protein free). For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Violet™ dye and mix until fully dissolved Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µL total staining volume intended for the assay. In the remaining volume, dilute Zombie Violet™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie Violet™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Violet™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death. Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS. Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells. Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Violet™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Violet™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Violet™. |
| Product Citations | Zhuo Y, et al. 2022. J Immunother Cancer. 10:. PubMed Vajda F, et al. 2022. Cells. 11:. PubMed Lareau CA, et al. 2023. Nat Protoc. 18:1416. PubMed Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed von Hofsten S, et al. 2023. Front Pharmacol. 14:1141669. PubMed Sun R, et al. 2023. PLoS One. 18:e0282722. PubMed Chaen T, et al. 2023. Biochem Biophys Rep. 34:101478. PubMed Laczkó-Rigó R, et al. 2021. Toxicol Appl Pharmacol. 429:115704. PubMed Tiu GC, et al. 2021. Dev Cell. 56:2089. PubMed Nourse JL, et al. 2022. J Gen Physiol. 154:. PubMed Fujii K, et al. 2021. Dev Cell. 56:2928. PubMed Bettke JA, et al. 2022. Infect Immun. 90:e0007022. PubMed Maughan EF, et al. 2022. iScience. 25:105409. PubMed Manzano-Muñoz A, et al. 2022. NPJ Precis Oncol. 6:90. PubMed Tsuzuki H, et al. 2022. Oncotarget. 13:1359. PubMed Tregoning JS, et al. 2023. Mol Ther Nucleic Acids. 31:29. PubMed Peng Q, et al. 2023. EMBO Rep. 24:e56034. PubMed Nyberg WA, et al. 2023. Cell. 186:446. PubMed Vondra S, et al. 2023. Cell Rep. 42:111977. PubMed Pan R, et al. 2022. Cell. 185:1521. PubMed Jaeger BN, et al. 2020. STAR Protoc. 1:100081. PubMed Donegan J, et al. 2016. Mol Psychiatry. 10.1038/mp.2016.121. PubMed Stanzione M, et al. 2022. Sci Adv. 8:eabn1229. PubMed Jiang Q, et al. 2022. Theranostics. 12:59. PubMed Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed Zhen A, et al. 2021. PLoS Pathog. 17:e1009404. PubMed Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed Arumugam T, et al. 2016. J Cereb Blood Flow Metab. 10.1177/0271678X16661201. PubMed Alcon C, et al. 2020. Cell Death Dis. 0.898611111. PubMed Meryk A et al. 2019. Cell reports. 26(10):2681-2691 . PubMed Ma X, et al. 2022. Cell Mol Immunol. . PubMed Barberio AE, et al. 2020. ACS Nano. 14:11238. PubMed Rothchild AC, et al. 2020. Bio Protoc. 10:00. PubMed Nath A, et al. 2015. Sci Rep. 5: 14752. PubMed Sun CC, et al. 2020. Genome Med. 0.553472222. PubMed Teunissen M, et al. 2022. Stem Cell Res Ther. 13:457. PubMed McComb S, et al. 2022. Front Immunol. 13:864868. PubMed Michaud D, et al. 2022. Front Immunol. 12:745873. PubMed Costa-Martins AG, et al. 2021. Cell Rep Med. 2:100465. PubMed Chen W, et al. 2021. Nat Microbiol. 6:455. PubMed Neidleman J, et al. 2020. Cell Rep Med. 100081:1. PubMed Knowles DA, et al. 2018. Elife. 7:e33480. PubMed Nielsen SS, et al. 2021. EBioMedicine. 68:103410. PubMed Wang Y, et al. 2021. Nat Commun. 12:2343. PubMed Kip P, et al. 2021. Nutrients. 13:. PubMed Xiao P, et al. 2022. Cell Death Dis. 13:476. PubMed Sugimoto C, et al. 2022. Elife. 11:. PubMed Canakci M, et al. 2020. Biomacromolecules. 21:2473. PubMed Cai EP, et al. 2020. Nat Metab. 0.731944444. PubMed McQuade A, et al. 2020. Nat Commun. 4.1875. PubMed Ma X et al. 2019. eLife. 8 pii: e42426. PubMed Hydes T, et al. 2017. Immun Inflamm Dis. 10.1002/iid3.190. PubMed Tang D, et al. 2020. Br J Haematol. 191:906. PubMed Vickman RE, et al. 2020. Prostate. 80:173. PubMed Akagi T, et al. 2022. Front Immunol. 13:926175. PubMed Shukla A, et al. 2021. Adv Nanobiomed Res. 1:. PubMed Pan Y, et al. 2021. Kidney Int. S0085-2538:001032. PubMed Michaud D, et al. 2020. Cytokine. 125:154817. PubMed Wei SC, et al. 2020. Cancer Discov. . PubMed Khan KA, et al. 2020. NPJ Breast Cancer. 6:29. PubMed Poonpanichakul T, et al. 2021. Front Immunol. 12:599805. PubMed Shepard A, et al. 2021. J Biol Chem. 297:100962. PubMed Gatla H, et al. 2022. Front Med Technol. 4:850565. PubMed Genuth NR, et al. 2022. Nat Commun. 13:5491. PubMed Busch CJ, et al. 2019. Bio Protoc. 9:e3302. PubMed Barman PK, et al. 2019. J Immunol. 202:2720. PubMed McLaughlin PA et al. 2019. PLoS Pathog. 15(7):e1007847 . PubMed Maritz MF, et al. 2018. PLoS One. 13:e0196043. PubMed Coelho PP, et al. 2022. Nat Commun. 13:3812. PubMed Luo W, et al. 2022. Front Immunol. 13:816761. PubMed Leonard NA, et al. 2021. Cancers (Basel). 13:. PubMed Prakash P, et al. 2021. Chem Sci. 12:10901. PubMed Sweeney EE, et al. 2020. Nano Res. 13:736. PubMed Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed Yu M, et al. 2020. Nat Commun. 11:515. PubMed Su S, et al. 2020. Mol Biol Cell. :mbcE20040232. PubMed Ward MC, et al. 2021. Elife. 10: . PubMed Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed Du Y, et al. 2022. Nat Commun. 13:231. PubMed Durham E, et al. 2019. Stem Cell Res. 40:101528. PubMed Ray RM, et al. 2019. Sci Rep. 9:4334. PubMed Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed Jones A, et al. 2015. J Immunol. 195: 1489-1497. PubMed Rai MA, et al. 2020. Retrovirology. 17:35. PubMed An Y, et al. 2021. Sci Rep. 6392:11. PubMed Surdziel E, et al. 2017. PLoS One.. 10.1371/journal.pone.0183679. PubMed He J, et al. 2019. J Clin Invest. 130. PubMed Hafner G, et al. 2019. Cell Rep. 28:3450. PubMed Hills LB, et al. 2021. J Immunol. 206:89. PubMed Hao C, et al. 2021. Frontiers in Cell and Developmental Biology. 9:695015. PubMed Coronel MM, et al. 2020. Sci Adv. 6:eaba5573. PubMed Doron H, et al. 2019. Cell Rep. 28:1785. PubMed Pothlichet J, et al. 2020. J Clin Invest. 130:2872. PubMed Bhattacharya A, et al. 2018. Neuropsychopharmacology. 43:2586. PubMed Kim MR, et al. 2020. Nat Commun. 3.681944444. PubMed Patir A, et al. 2020. Sci Rep. 10:21047. PubMed Valeff NJ, et al. 2022. Front Immunol. 13:873493. PubMed Rogers LM, et al. 2020. Cancer Immunol Res. 1206:8. PubMed Kanemaru K, et al. 2015. PLoS One. 10: 0144436. PubMed Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed Wohlfahrt T, et al. 2019. Nature. 566:344. PubMed Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed de la Fuente AG, et al. 2020. Mol Cell Proteomics. 1.68125. PubMed de la Fuente AG, et al. 2020. Mol Cell Proteomics. 19:1281. PubMed Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed Manzano-Muñoz A, et al. 2021. Front Cell Dev Biol. 9:695225. PubMed Hurov K, et al. 2021. J Immunother Cancer. 9:. PubMed Câmara DR, et al. 2022. Reprod Domest Anim. 57:10. PubMed Lopez P, et al. 2022. Cell Rep. 38:110406. PubMed Lim RM, et al. 2020. ACS Chem Biol. 15:2299. PubMed Li MY, et al. 2021. Developmental Cell. 56:2547. PubMed Oprescu SN, et al. 2020. STAR Protoc. 1:100051. PubMed Ward MC, et al. 2019. Elife. 8. PubMed Bradley T et al. 2018. Cell reports. 25(1):107-117 . PubMed Alcon C, et al. 2021. Cells. 10:. PubMed Pali-Schöll I, et al. 2022. Clin Transl Allergy. 12:e12125. PubMed Deng Y, et al. 2021. Nat Commun. 12:7041. PubMed Palmerin N, et al. 2021. Viruses. 13:. PubMed Phan TS, et al. 2021. Sci Adv. 7:. PubMed Babon J, et al. 2016. Nat Med. 10.1038/nm.4203. PubMed Rothchild A, et al. 2016. Proc Natl Acad Sci U S A. 113: E6172 - E6181. PubMed Messerer DAC, et al. 2020. Front Immunol. 11:571992. PubMed Enyedi K, et al. 2017. PLoS One. 12(6):e0178632. PubMed Vickman RE, et al. 2019. Mol Cancer Res. 17:1253. PubMed Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed Wang YJ, et al. 2021. Sci Rep. 11:8054. PubMed Denoth-Lippuner A, et al. 2021. Cell Stem Cell. 28:2020. PubMed Sobecki M, et al. 2022. Cell Stem Cell. 29:1459. PubMed Wang Y, et al. 2021. Cell Reports. 36(6):109516. PubMed Ye J, et al. 2019. Front Oncol. 8:631. PubMed Boehm D et al. 2017. Cell host & microbe. 21(5):569-579 . PubMed Yue F, et al. 2022. Cell Rep. 38:110267. PubMed Malani D, et al. 2021. Cancer Discov. Online ahead of print. PubMed Forconi CS, et al. 2021. Cancers (Basel). 13:. PubMed Maillet A, Tan K, and Brunham L. 2017. Curr Protoc Toxicol. 10.1002/cptx.30. PubMed Ulferts R, et al. 2021. Cell Rep. 37:109899. PubMed Yoon YJ, et al. 2022. Nat Commun. 13:3291. PubMed Oliveira ERA, et al. 2021. Viruses. 13:. PubMed Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed Köhler VK, et al. 2020. Int J Mol Sci. 21:00. PubMed Alomari N, et al. 2022. Viruses. 14:. PubMed Cao S, et al. 2022. Nat Commun. 13:4684. PubMed |
|---|
| Biology Area | Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience |
|---|
| Gene ID | NA |
|---|
| Regulatory Status | RUO |
|---|
| Other Names | Fixable Dye, Fixable Viability Dye, Dead, Apoptosis |
|---|